PH12017500010B1 - Methods for the treatment of hepatitis b and hepatitis d virus infections - Google Patents

Methods for the treatment of hepatitis b and hepatitis d virus infections

Info

Publication number
PH12017500010B1
PH12017500010B1 PH1/2017/500010A PH12017500010A PH12017500010B1 PH 12017500010 B1 PH12017500010 B1 PH 12017500010B1 PH 12017500010 A PH12017500010 A PH 12017500010A PH 12017500010 B1 PH12017500010 B1 PH 12017500010B1
Authority
PH
Philippines
Prior art keywords
hepatitis
treatment
virus
methods
virus infections
Prior art date
Application number
PH1/2017/500010A
Other languages
English (en)
Other versions
PH12017500010A1 (en
Inventor
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12017500010(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of PH12017500010A1 publication Critical patent/PH12017500010A1/en
Publication of PH12017500010B1 publication Critical patent/PH12017500010B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
PH1/2017/500010A 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections PH12017500010B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US201462091943P 2014-12-15 2014-12-15
PCT/CA2015/050626 WO2016004525A1 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Publications (2)

Publication Number Publication Date
PH12017500010A1 PH12017500010A1 (en) 2017-05-15
PH12017500010B1 true PH12017500010B1 (en) 2022-07-29

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2017/500010A PH12017500010B1 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Country Status (33)

Country Link
US (1) US9603865B2 (enExample)
EP (1) EP3166615B1 (enExample)
JP (2) JP2017521433A (enExample)
KR (2) KR102734495B1 (enExample)
CN (2) CN106659730A (enExample)
AU (1) AU2015286199B2 (enExample)
BR (1) BR112017000320B1 (enExample)
CA (1) CA2954182C (enExample)
CL (1) CL2017000008A1 (enExample)
CU (1) CU20170001A7 (enExample)
DK (1) DK3166615T3 (enExample)
DO (1) DOP2017000002A (enExample)
EA (1) EA036745B1 (enExample)
EC (1) ECSP16097355A (enExample)
ES (1) ES2963814T3 (enExample)
FI (1) FI3166615T3 (enExample)
HK (1) HK1231402A1 (enExample)
HR (1) HRP20231400T1 (enExample)
HU (1) HUE064449T2 (enExample)
IL (1) IL249660B (enExample)
LT (1) LT3166615T (enExample)
MD (1) MD4760C8 (enExample)
MX (1) MX381042B (enExample)
MY (1) MY178087A (enExample)
PH (1) PH12017500010B1 (enExample)
PL (1) PL3166615T3 (enExample)
PT (1) PT3166615T (enExample)
RS (1) RS64833B1 (enExample)
SG (1) SG11201700073PA (enExample)
SI (1) SI3166615T1 (enExample)
SM (1) SMT202300380T1 (enExample)
TW (1) TWI766831B (enExample)
WO (1) WO2016004525A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3853240A4 (en) * 2018-11-08 2022-11-30 Aligos Therapeutics, Inc. S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20210189392A1 (en) * 2019-12-12 2021-06-24 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CN112010905B (zh) * 2020-05-07 2021-09-03 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦晶型及其应用
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
AU2021383758A1 (en) * 2020-11-20 2023-06-15 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
CN117616121A (zh) 2021-07-09 2024-02-27 葛兰素史密斯克莱知识产权(第3号)有限公司 寡核苷酸用于具有肾脏损伤的个体的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
NZ538719A (en) 2002-09-13 2008-05-30 Replicor Inc Non-sequence complementary antiviral oligonucleotides
US9474793B2 (en) * 2005-02-22 2016-10-25 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus
PH12013500192B1 (en) 2010-08-20 2018-11-23 Replicor Inc Oligonucleotide chelate complexes
ES2663009T3 (es) * 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
RS62030B1 (sr) * 2012-05-18 2021-07-30 Replicor Inc Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
CA2883785C (en) * 2012-08-30 2020-08-18 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
SG11201700073PA (en) 2017-02-27
CA2954182A1 (en) 2016-01-14
KR20230070330A (ko) 2023-05-22
KR102734495B1 (ko) 2024-11-25
EP3166615A1 (en) 2017-05-17
EP3166615A4 (en) 2018-01-17
CU20170001A7 (es) 2017-04-05
EA036745B1 (ru) 2020-12-16
MY178087A (en) 2020-10-02
MD20170014A2 (ro) 2017-07-31
FI3166615T3 (fi) 2023-11-06
MD4760C8 (ro) 2022-02-28
HK1231402A1 (zh) 2017-12-22
EA201790160A1 (ru) 2017-06-30
PL3166615T3 (pl) 2024-02-19
NZ727583A (en) 2024-08-30
WO2016004525A1 (en) 2016-01-14
KR20170029577A (ko) 2017-03-15
RS64833B1 (sr) 2023-12-29
IL249660A0 (en) 2017-02-28
HRP20231400T1 (hr) 2024-02-16
AU2015286199B2 (en) 2020-05-14
HUE064449T2 (hu) 2024-03-28
LT3166615T (lt) 2024-01-25
CN113750112A (zh) 2021-12-07
BR112017000320A2 (pt) 2017-11-07
BR112017000320B1 (pt) 2023-02-07
MX381042B (es) 2025-03-12
US9603865B2 (en) 2017-03-28
IL249660B (en) 2022-02-01
JP2020143065A (ja) 2020-09-10
CL2017000008A1 (es) 2017-06-09
ES2963814T3 (es) 2024-04-02
CN106659730A (zh) 2017-05-10
JP2017521433A (ja) 2017-08-03
PH12017500010A1 (en) 2017-05-15
EP3166615B1 (en) 2023-08-09
MD4760B1 (ro) 2021-07-31
TW201613617A (en) 2016-04-16
SI3166615T1 (sl) 2023-12-29
TWI766831B (zh) 2022-06-11
CA2954182C (en) 2023-08-15
JP6922030B2 (ja) 2021-08-18
MX2017000053A (es) 2017-05-01
US20160008393A1 (en) 2016-01-14
ECSP16097355A (es) 2017-03-31
PT3166615T (pt) 2023-11-13
AU2015286199A1 (en) 2017-02-23
DOP2017000002A (es) 2017-03-15
SMT202300380T1 (it) 2024-01-10
DK3166615T3 (da) 2023-11-13

Similar Documents

Publication Publication Date Title
MY178087A (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
PH12017500614A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
HK1248278A1 (zh) 用於使乙型肝炎病毒基因表达沉默的组合物及方法
ZA201901061B (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
SG11201801809VA (en) Method for modifying genome sequence that specifically converts nucleobase of targeted dna sequence, and molecular complex used in said method
WO2016183366A3 (en) Compositions and methods for silencing expression of hepatitis d virus rna
MX2016002586A (es) Métodos y composiciones para el tratamiento guiado por rna de infección por hiv.
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
MX373703B (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
WO2015042308A3 (en) Rna-based hiv inhibitors
SG11202003461TA (en) NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION
HK1251010A1 (zh) 用於治疗乙型肝炎病毒(hbv)感染的试剂及用途
PH12018502320A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
MA40218A (fr) Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d
NZ727583B2 (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
HK40109846A (zh) 减少papd5和papd7 mrna的核酸分子用於治疗乙型肝炎感染
IL286484A (en) Reagents for the treatment and use of hepatitis B infection
HK40008711A (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
AU2015901617A0 (en) Reagents for treatment of hepatitis B virus (HBV) infection and use thereof